AngioDynamics, Inc. (ANGO)

From the record

AngioDynamics, Inc.'s filings since 2017 show no warning events in the scan: no bankruptcy or receivership notice, no debt default notice, no exchange listing notice, no restatement warning, no auditor change, no material cyber incident and no late-report notice (its current reports).

From the record

AngioDynamics, Inc.'s 7 filed years say what it did: revenue went from $264 million in fiscal 2020 to $320 million in fiscal 2026, up 3.3% a year; it rose in 4 of 6 years; the deepest fall was 14% from fiscal 2023 to fiscal 2025; net income was positive in 0 of 7 of those years (its annual reports).

From the record

Return on equity: in the fiscal year ended 2026-05-31, AngioDynamics, Inc. lost about 22 cents for every dollar of shareholders' money, and gross profitability: its products earned about 65 cents per dollar of everything the company owns. Leverage: it owed about 36 cents per dollar of assets, and net share issuance: its share count grew 1.6% over the year (the filed statements).

From the record

AngioDynamics, Inc.'s standing among 109 graded names in its industry family: revenue of $320 million in fiscal 2026 ranks in the top 32% by size; a net margin of -11.5% ranks in the top 43%; revenue growth of -1.9% a year over the last 3 filed years ranks in the bottom 19% (its annual reports).

From the record

AngioDynamics, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Honroth, Eric (President and CEO, as filed), filing under that title since 2026-11-04, under a month (bottom 1% of its family); the 14 officers and directors filing in the last fifteen months have been on the record a median of 8.4 years (top 14%); 7 officer or director changes were reported on Form 8-K since 2023-11-13, against the 14 people in charge now (top 48%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

AngioDynamics, Inc.'s room to grow, from the newest filed statements (fiscal 2026): cash of $54 million against no long-term debt tagged leaves 20.2% of its assets as net cash, top 37% of its family; cash from operations less capital spending is 0.2% of revenue (top 40%); a gross margin of 54.6% (bottom 37%); research spending of 9.2% of revenue (bottom 40%) (its annual report).

From the record

AngioDynamics, Inc.'s growth drivers, from the filed years to fiscal 2026: revenue grew -1.9% a year over the last three filed years against 3.3% over all 7, slowing (bottom 35% of its family); the newest year grew 9.5% (bottom 39%); research spending grew -0.5% a year (bottom 32%); capital spending grew -12.2% a year (bottom 36%) (its annual reports). AngioDynamics, Inc. reported 2 lines of business in fiscal 2026: Med Device at $170 million (53%), Med Tech at $150 million (47%); 2 of 2 grew against the year before (its annual report).

From the record

AngioDynamics, Inc.'s newest year against its own record: revenue of $320 million in fiscal 2026 came in 17.8% above the $272 million its prior three years' pace pointed to (top 11% of its family); net income of $37 million against a prior three-year average of $90 million (top 30%); a net margin of -11.5% against -29.3% before (top 38%) (its annual reports).